Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Scinai Immunotherapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SCNI
Nasdaq
8731
https://www.scinai.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
- May 6th, 2024 1:21 pm
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
- Apr 10th, 2024 11:00 am
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
- Apr 8th, 2024 11:00 am
Scinai leadership to attend BIO-Europe Spring 2024
- Mar 12th, 2024 12:00 pm
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
- Feb 29th, 2024 1:45 pm
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
- Feb 13th, 2024 12:00 pm
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
- Jan 25th, 2024 3:26 pm
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
- Jan 4th, 2024 9:01 pm
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
- Jan 4th, 2024 11:15 am
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
- Dec 29th, 2023 2:21 pm
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
- Dec 27th, 2023 12:15 pm
Scinai Announces Promising Results in a Psoriatic Human Skin Model
- Dec 12th, 2023 12:26 pm
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
- Dec 11th, 2023 1:11 pm
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
- Nov 29th, 2023 2:25 pm
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule
- Nov 20th, 2023 12:30 pm
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
- Nov 6th, 2023 12:30 pm
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
- Nov 3rd, 2023 8:30 pm
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
- Oct 31st, 2023 1:00 pm
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
- Oct 31st, 2023 12:23 pm
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
- Oct 30th, 2023 11:00 am
Scroll